Clinical trials: Select Advanced Malignancies
Endometrial Carcinoma, Neoplasms, Endometrial
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
This is an open-label study, meaning both the researchers and participants will know which treatment is being given. The study has two parts. In Part 1, researchers will identify the most suitable SC dose.
- Trial name
- SAPPHIRE (NCT07860450)
- Testing
- Dostarlimab, Carboplatin and paclitaxel
- Volunteers
- 378 people
- Sponsor
- GlaxoSmithKline
Solid Tumors
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in…
- Trial name
- NCT04613492
- Testing
- MEDI9253, Durvalumab
- Where
- 8 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Breast Cancer, Liver Cancer
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical…
- Conditions
- Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- ESCAT (NCT06958224)
- Testing
- Large and early multigene sequencing
- Where
- France
- Volunteers
- 360 people
- Sponsor
- University Hospital, Lille
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
Locally Advanced or Metastatic Unresectable Urothelial Cancer
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable…
- Trial name
- TROPiCS-04 (NCT04527991)
- Testing
- Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel
- Where
- 234 sites in United States, Australia and 25 more
- Volunteers
- 711 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected…
- Trial name
- STELLAR-001 (NCT03665129)
- Testing
- IPH5401 and Durvalumab
- Where
- 12 sites in United States, France
- Volunteers
- 73 people
- Sponsor
- Innate Pharma
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Pevonedistat is a medicine to treat people with blood cancers or solid tumors. The main aim of the study is to learn about the levels of pevonedistat in the blood of participants with blood cancers or solid tumors, who also have…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency
- Trial name
- NCT03814005
- Testing
- Azacitidine, Pevonedistat
- Where
- 8 sites in United States, Spain
- Volunteers
- 17 people
- Sponsor
- Takeda
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT05361720
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Colorectal Cancer, Colon Cancer
A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer
This is a first-in-human Phase 1 study of DEM301 in adults with previously treated advanced metastatic colorectal cancer. DEM301 is an investigational antibody-drug conjugate.
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT07805369
- Testing
- DEM301
- Where
- 2 sites in Australia
- Volunteers
- 60 people
- Sponsor
- DEM BioPharma, Inc.
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Neoplasms
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of…
- Trial name
- NCT07438782
- Testing
- GSK5533524
- Where
- 20 sites in United States, Canada and 6 more
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Breast Cancer, HER2 Positive Breast Cancer
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus…
- Trial name
- HERMIONE (NCT02213744)
- Testing
- MM-302, Gemcitabine, Capecitabine
- Where
- 109 sites in United States, Austria and 7 more
- Volunteers
- 113 people
- Sponsor
- Merrimack Pharmaceuticals
Advanced Cancers
Rational Therapeutics Based on Matched Tumor and Normal Tissue
The goal of this laboratory research study is to learn if using molecular information (matched therapy) or not using molecular information and having the study doctor choose the therapy based on your past experience are more…
- Trial name
- NCT02272595
- Testing
- Treatment Based on Genetic Mutation, Treatment Based on No Genetic Mutation
- Where
- 4 sites in United States, France and 2 more
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
This clinical trial evaluated the safety and potential benefits of combining two cancer treatments, tislelizumab and lenvatinib, in Chinese participants with advanced or metastatic cancers, including lung, head and neck, bladder…
- Trial name
- NCT05014828
- Testing
- lenvatinib, Tislelizumab
- Where
- 13 sites in China
- Volunteers
- 58 people
- Sponsor
- BeiGene
Colorectal Cancer
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
- Trial name
- NCT07722494
- Testing
- IBI363 + bevacizumab, Investigator's choice of therapy
- Where
- 2 sites in China
- Volunteers
- 550 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumours
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study.
- Trial name
- NCT06581432
- Testing
- Zongertinib
- Where
- 92 sites in United States, Australia and 14 more
- Volunteers
- 588 people
- Sponsor
- Boehringer Ingelheim
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous non-small cell lung cancer.
- Trial name
- NCT04974957
- Testing
- SHR-1701；BP102
- Volunteers
- 71 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.